Loading...
Clinicians are keenly interested in identifying the best approach to pharmacologic treatment of hypertension, found in 73 million people in the U.S. and 1 billion in the world. In the manufacturer-sponsored Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, researchers compared two combination treatments: an ACE inhibitor plus either a thiazide diuretic or a calcium channel blocker (CCB). All participants had hypertension in addition to impaired renal function, peripheral artery disease, LV hypertrophy, diabetes, a history of coronary events, or a combination of these conditions. The primary endpoint was a composite of cardiovascular death and cardiovascular events.
Th…